登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《LANCET，5月28日，COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-05-29

  • COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

    Lennard Y W Lee, DPhil *

    Prof Jean Baptiste Cazier, PhD *

    T Starkey, MSc

    C D Turnbull, DPhil

    UK Coronavirus Cancer Monitoring Project Team

    Rachel Kerr, FRCP †

    et al.

    Show all authors

    Show footnotes

    Published:May 28, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31173-9

    Summary

    Background

    Individuals with cancer, particularly those who are receiving systemic anticancer treatments, have been postulated to be at increased risk of mortality from COVID-19. This conjecture has considerable effect on the treatment of patients with cancer and data from large, multicentre studies to support this assumption are scarce because of the contingencies of the pandemic. We aimed to describe the clinical and demographic characteristics and COVID-19 outcomes in patients with cancer.

    Methods

    In this prospective observational study, all patients with active cancer and presenting to our network of cancer centres were eligible for enrolment into the UK Coronavirus Cancer Monitoring Project (UKCCMP). The UKCCMP is the first COVID-19 clinical registry that enables near real-time reports to frontline doctors about the effects of COVID-19 on patients with cancer. Eligible patients tested positive for severe acute respiratory syndrome coronavirus 2 on RT-PCR assay from a nose or throat swab. We excluded patients with a radiological or clinical diagnosis of COVID-19, without a positive RT-PCR test. The primary endpoint was all-cause mortality, or discharge from hospital, as assessed by the reporting sites during the patient hospital admission.

  • 原文来源：https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31173-9/fulltext
98浏览量
原文链接
相关报告

  • 《Lancet，5月28日，Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-05-29
    • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Nicole M Kuderer, MD † Toni K Choueiri, MD † Dimpy P Shah, PhD † Yu Shyr, PhD † Samuel M Rubinstein, MD Donna R Rivera, PharmD et al. Published:May 28, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31187-9 Summary Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness. Methods In this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using logistic regression analyses, partially adjusted for age, sex, smoking status, and obesity. This study is registered with ClinicalTrials.gov, NCT04354701, and is ongoing.
    138浏览量
    原文链接

  • 《LANCET，5月29日，Anakinra for severe forms of COVID-19: a cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-30
    • Anakinra for severe forms of COVID-19: a cohort study Thomas Huet, MD Hélène Beaussier, Pharm D Olivier Voisin, MD Stéphane Jouveshomme, MD Gaëlle Dauriat, MD Isabelle Lazareth, MD et al. Show all authors Published:May 29, 2020DOI:https://doi.org/10.1016/S2665-9913(20)30164-8 Summary Background Coronaviruses can induce the production of interleukin (IL)-1β, IL-6, tumour necrosis factor, and other cytokines implicated in autoinflammatory disorders. It has been postulated that anakinra, a recombinant IL-1 receptor antagonist, might help to neutralise the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related hyperinflammatory state, which is considered to be one cause of acute respiratory distress among patients with COVID-19. We aimed to assess the off-label use of anakinra in patients who were admitted to hospital for severe forms of COVID-19 with symptoms indicative of worsening respiratory function. Methods The Ana-COVID study included a prospective cohort from Groupe Hospitalier Paris Saint-Joseph (Paris, France) and a historical control cohort retrospectively selected from the Groupe Hospitalier Paris Saint-Joseph COVID cohort, which began on March 18, 2020. Patients were included in the prospective cohort if they were aged 18 years or older and admitted to Groupe Hospitalier Paris Saint-Joseph with severe COVID-19-related bilateral pneumonia on chest x-ray or lung CT scan. The other inclusion criteria were either laboratory-confirmed SARS-CoV-2 or typical lung infiltrates on a lung CT scan, and either an oxygen saturation of 93% or less under oxygen 6 L/min or more, or aggravation (saturation ≤93% under oxygen 3 L/min) with a loss of 3% of oxygen saturation in ambient air over the previous 24 h. The historical control group of patients had the same inclusion criteria. Patients in the anakinra group were treated with subcutaneous anakinra (100 mg twice a day for 72 h, then 100 mg daily for 7 days) as well as the standard treatments at the institution at the time. Patients in the historical group received standard treatments and supportive care. The main outcome was a composite of either admission to the intensive care unit (ICU) for invasive mechanical ventilation or death. The main analysis was done on an intention-to-treat basis (including all patients in the anakinra group who received at least one injection of anakinra).
    32浏览量
    原文链接